[go: up one dir, main page]

MX2017000142A - Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica. - Google Patents

Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.

Info

Publication number
MX2017000142A
MX2017000142A MX2017000142A MX2017000142A MX2017000142A MX 2017000142 A MX2017000142 A MX 2017000142A MX 2017000142 A MX2017000142 A MX 2017000142A MX 2017000142 A MX2017000142 A MX 2017000142A MX 2017000142 A MX2017000142 A MX 2017000142A
Authority
MX
Mexico
Prior art keywords
stromal cells
mesenchymal stromal
treating sepsis
sepsis
treating
Prior art date
Application number
MX2017000142A
Other languages
English (en)
Other versions
MX381544B (es
Inventor
Dekker Robert
Lombardo Eleuterio
Dalemans Wilfried
Original Assignee
Tigenix S A U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigenix S A U filed Critical Tigenix S A U
Publication of MX2017000142A publication Critical patent/MX2017000142A/es
Publication of MX381544B publication Critical patent/MX381544B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)

Abstract

La invencion se refiere al uso de celulas estromales mesenquimatosas (MSCs) para tratar la sepsis en un sujeto. La invencion proporciona composiciones, usos y metodos para el tratamiento de la sepsis.
MX2017000142A 2014-06-30 2015-06-30 Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto. MX381544B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14175095 2014-06-30
PCT/IB2015/054923 WO2016001846A1 (en) 2014-06-30 2015-06-30 Mesenchymal stromal cells for treating sepsis

Publications (2)

Publication Number Publication Date
MX2017000142A true MX2017000142A (es) 2017-07-28
MX381544B MX381544B (es) 2025-03-12

Family

ID=51033023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000142A MX381544B (es) 2014-06-30 2015-06-30 Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.

Country Status (14)

Country Link
US (2) US20170151284A1 (es)
EP (1) EP3160481B1 (es)
JP (1) JP6722599B2 (es)
KR (1) KR102213527B1 (es)
CN (1) CN106573017B (es)
AU (1) AU2015283662B2 (es)
BR (1) BR112016030758B8 (es)
CA (1) CA2953884C (es)
IL (1) IL249814B (es)
MX (1) MX381544B (es)
NZ (1) NZ727950A (es)
RU (1) RU2715866C2 (es)
SG (1) SG11201610844PA (es)
WO (1) WO2016001846A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3385372B1 (en) * 2015-12-01 2023-08-09 AdipoSeeds, Inc. Method for manufacturing mesenchymal cell line derived from vertebrate animal adipose tissue
WO2017156235A1 (en) * 2016-03-09 2017-09-14 Emory University Methods of preserving mesenchymal stem cells
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
PT3589298T (pt) 2017-02-28 2022-09-22 Univ De Lorraine Células estaminais mesenquimatosas obtidas a partir da geleia de wharton para o tratamento de sépsis
US11524000B2 (en) 2017-10-26 2022-12-13 Emory University Targeting Mcl-1 to enhance DNA replication stress sensitivity for cancer therapy
CN112261943B (zh) * 2018-06-05 2024-11-15 Medipost株式会社 用于预防或治疗炎症性疾病的包含间充质干细胞作为有效成分的药物组合物
KR20210086662A (ko) * 2018-10-29 2021-07-08 오타와 하스피털 리서치 인스티튜트 Aoah를 과발현하는 유전자조작된 중간엽 줄기 세포 및 이의 용도
US20230086254A1 (en) * 2020-01-30 2023-03-23 Jcr Pharmaceuticals Co., Ltd. Medicinal composition comprising dental pulp-derived cells
CA3220002A1 (en) * 2021-05-13 2022-11-17 Primegen Us, Inc. Methods and compositions for treating liver disease
CN113398150A (zh) * 2021-06-18 2021-09-17 卡替(上海)生物技术有限公司 牙髓间充质干细胞在脓毒症治疗中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627175A (en) 1992-12-02 1997-05-06 Shellinternationale Research Maatschappij B.V. Azoxycyanobenzene compounds
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
CA2222328C (en) 1995-06-07 2012-01-10 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US5705308A (en) 1996-09-30 1998-01-06 Eastman Kodak Company Infrared-sensitive, negative-working diazonaphthoquinone imaging composition and element
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
EP2824175B2 (en) * 2004-03-22 2020-10-28 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
WO2007039150A2 (en) 2005-09-23 2007-04-12 Cellerix, S.L. Cell populations having immunoregulatory activity, method for isolation and uses
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
ES2629502T3 (es) * 2011-03-11 2017-08-10 Children's Medical Center Corporation Métodos y composiciones relacionados con exosomas de células madre mesenquimales
JP2014016782A (ja) * 2012-07-09 2014-01-30 Toshiba Corp 情報処理装置およびプログラム
US20140134140A1 (en) * 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections

Also Published As

Publication number Publication date
RU2016151738A3 (es) 2019-01-30
BR112016030758B1 (pt) 2021-10-13
WO2016001846A1 (en) 2016-01-07
CA2953884A1 (en) 2016-01-07
AU2015283662A1 (en) 2017-01-19
US20170151284A1 (en) 2017-06-01
SG11201610844PA (en) 2017-01-27
AU2015283662B2 (en) 2020-09-24
CN106573017A (zh) 2017-04-19
KR20170021343A (ko) 2017-02-27
IL249814B (en) 2020-02-27
EP3160481A1 (en) 2017-05-03
CN106573017B (zh) 2021-06-11
JP6722599B2 (ja) 2020-07-15
RU2016151738A (ru) 2018-07-30
US20200376038A1 (en) 2020-12-03
JP2017520583A (ja) 2017-07-27
KR102213527B1 (ko) 2021-02-09
BR112016030758B8 (pt) 2022-10-25
BR112016030758A2 (es) 2017-08-22
IL249814A0 (en) 2017-03-30
CA2953884C (en) 2022-12-06
NZ727950A (en) 2022-07-01
RU2715866C2 (ru) 2020-03-03
MX381544B (es) 2025-03-12
EP3160481B1 (en) 2020-09-09

Similar Documents

Publication Publication Date Title
MX2017000142A (es) Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.
CY1123065T1 (el) Ανασυνδυασμενα προβιοτικα βακτηριδια
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
SA517381769B1 (ar) توليد حمض بيروكسي فورميك من خلال فورمات كحول بولي هيدريك
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201790273A1 (ru) Флагеллиновые композиции и их применение
CL2016001840A1 (es) Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer.
BR112017006664A2 (pt) terapias de combinação
EA201692098A1 (ru) Биокерамические композиции и их применение для биомодулирования
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
UY37018A (es) Inhibidores bicíclicos de pad4
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX373129B (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
CL2015002897A1 (es) Inhibidores de bace1
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
MX2017003953A (es) Compuestos que contrarrestan el mal olor bajo, de cobertura-alta y metodos uso.
MX386860B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
BR112018008931A2 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
MX2017000306A (es) Metodos para tratar hipotension.